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It has been long accepted that many types of B cell cancer 
(lymphomas, myelomas, plasmacytomas, etc) are derived from the  
antigen-stimulated B cell Germinal Center (GC) reaction [1-4] i.e. 
they are aberrant products of the somatic hypermutation 
mechanism normally targeting rearranged  immunoglobulin (Ig) 
variable genes (so called V[D]J regions). Here we provide evidence 
that the somatic mutation patterns of some well characterised 
cancer genomes [5] such as lung carcinomas, breast carcinomas 
and squamous cell carcinomas, strongly resemble in toto or in part 
the spectrum of somatic point mutations observed in normal 
physiological somatic hypermutation (SHM) in antibody variable 
genes [6]. This implies that whilst SHM itself is a tightly regulated 
and beneficial mutational process for B lymphocytes of the immune 
system, aberrant mutations (or "crises") or inadvertent activation of 
this complex activation-induced cytidine deaminase (AID)-
dependent mechanism in a range of somatic tissue types could 
result, as often speculated [7], in cancer. 
 In normal physiological Ig SHM two main groups of strand-
biased mutations are known to occur: (i) at A:T base pairs whereby 
A mutations exceed T mutations by 2-3 fold; and (ii) at G:C base 
pairs whereby G mutations exceed C mutations by at least 1.7 fold. 
A critical analysis of the SHM literature in experimental mouse 
systems of the past 25 years [6] shows that these strand-biased 
mutation spectra are best understood as occurring first in RNA 
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molecules which are then copied back into DNA most likely by a 
cellular reverse transcription (RT) process carried out by the sole 
error-prone DNA polymerase [6] known to be involved in SHM, DNA 
polymerase–η (eta) ; which also happens to be a relatively efficient 
reverse transcriptase [8] being active on dilution at low mole ratios 
of enzyme-to-template in vitro (1:20-1:100). Thus, whilst it has 
been clearly established that AID deaminase initiates SHM and Ig 
class switching by direct deamination of C-to-U in ssDNA in the 
context of transcription [9] the full mutation spectrum of SHM 
appears to be generated by the synthesis of, modification of and 
RT-copying of the Ig pre-mRNA template ie. most Ig somatic 
mutations appear first as “RNA mutations” which are then copied 
back into B lymphocyte genomic DNA [6]. The elements of this 
proposal were first advanced by Steele & Pollard in 1987 [10]. Thus 
the A>>T strand biased mutation pattern is best understood as a 
combination of adenosine-to-inosine (A-to-I) pre-mRNA editing [11] 
followed by an error-prone Pol-η dependent reverse transcription 
step fixing the A-to-G, as well as A-to-T and A-to-C, as strand 
biased mutations in B cell DNA [6,11].  The G>>C strand biased 
mutation pattern, only recently recognised, is consistent with the 
misincorporation signature of RNA polymerase II [6] transcribing 
template DNA strands carrying AID-mediated lesions generated at C 
bases viz. uracils and abasic sites [12]. Again a reverse 
transcription step presumably involving Pol-η would then need to 
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intervene to fix the RNA mutation pattern in DNA. Possible 
molecular mechanisms and substrates have been discussed 
elsewhere [6]. Here we turn our attention to human cancer and 
question whether these insights can be of use in understanding the 
genesis of the somatic mutation spectra observed for a range of 
cancer genomes from different tissue types.  
 Our understanding of the fundamental mechanisms causing 
somatic mutations in human cancer cells is still relatively 
rudimentary. However SHM in the vertebrate immune system is one 
well characterised situation of a highly regulated beneficial mutator 
process where we now have a good understanding of the 
mechanism albeit incomplete [6]. Thus somatic point mutations are 
focused on a 1-2 kb region targeting V[D]J genes in GC B 
lymphocytes and intense antigen-binding selection ensures that 
mutated B cells bearing surface Ig antigen receptors with similar or 
better binding affinity for antigen survive, proliferate and become 
part of the memory B cell pool. It is therefore conceivable, as 
suggested by Honjo and associates for example [7], that 
disturbances in the regulation of this system in non-lymphoid 
somatic cells may unleash an uncontrolled spray or shower of 
somatic point mutations, and thus contribute to the development of 
cancer (Figure 1).  
 For a preliminary analysis to test the feasibility of this idea we 
choose a subset of the well curated cancer genome data base at 
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The Welcome Trust Sanger Institute website [5]. The data sampled 
are at: 
http://www.sanger.ac.uk/genetics/CGP/Studies/  
The mutation patterns in individual tumour cell lines (or tissue 
biopsies) included in our analysis were specifically in the "Capillary 
Screen Data/ Protein Kinase Gene Analysis" at 
http://www.sanger.ac.uk/perl/genetics/CGP/cgp_viewer?action=stu
dy&study_id=34 for Samples BB30-HNC down to PD2543a. 
 To allow valid comparisons between somatic mutation 
patterns it was necessary in all previous SHM analyses [6] to 
establish the most likely somatic mutations that occur in vivo during 
an immune response. Such a pattern would be free of confounding 
strand-bias blunting effects due to PCR product artefacts (PCR 
hybrid or recombinant molecules). This is explained in a previous 
publication [6]. Thus Table 1a shows a true and typical pattern of 
somatic point mutations observed at rearranged Ig loci in mice 
undergoing an antibody response (also Table 1a in ref. 6). All 
mutations are read from the non-transcribed strand, and all 
mutation frequencies (expressed as %) have been corrected for 
slight differences in the base composition of the V[D]J target areas 
assayed for somatic mutations (typically 300-400 bp).  It is found 
that the mutations off A exceed the mutations off T by 2.9 fold, and 
the mutations off G exceed the mutations off C by 1.7 fold. We 
interpret these strand bias patterns as being reflective of the 
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nucleotide sequence errors generated in the Ig mRNA during SHM, 
and which are then copied back into DNA (see Fig 5 in ref.6).   
In the samples of the Cancer Genome Project (CGP) analysed 
here, it is found that the somatic mutation spectra of lung 
adenocarcinomas (Table 1b), lung small cell carcinomas (Table 1c), 
breast ductal carcinomas (Table 1d) and squamous cell carcinomas 
(Table 1e) in many cases strongly resemble in toto or in part the 
strand biased patterns typical of Ig SHM (Table 1a). Unlike Ig genes 
where we have been able to correct for base composition we have 
had to assume base composition "evening-out" effects: this is not 
an unreasonable assumption given the large number of mutated 
cancer-associated genes involved. It is also found that different 
types of cancer show some quite distinct variations in the basic 
strand bias pattern observed. For example, and as pointed out by 
Greenman et al [5], some cancers such as skin malignant 
melanomas have more restricted spectra with mutations highly 
focused to C:G base pairs with mutations at A:T base pairs 
suppressed (Table 1f). Such a pattern is typical of the AID 
deaminase footprint of SHM at the Ig locus established by 
Neuberger and colleagues for mice lacking uracil DNA glycosylase 
and functional mismatch repair machinery, MSH2-MSH6 [13,14]. 
However in contrast to that data we do not see an excess of C-to-T 
over G-to-A mutations suggestive of AID-mediated deamination 
preferentially on the displaced non-transcribed strand during 
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transcription [6]. We have also found that tumors with 
comparatively large numbers of somatic mutations, such as NCI-
H2009 (lung adenocarcinoma, Table 1g) and CP66-MEL (malignant 
melanoma, Table 1h), display somatic mutation spectra similar to 
the pooled data for that tumor category (Table 1b and 1f 
respectively). A comparison of the somatic mutation spectra of the 
pooled data and the individual data set adds weight to the view that 
different tissue tumor types can display different somatic mutation 
spectra as shown by Greenman et al [5]. This is intriguing in the 
context of the overall resemblance of these tissue-specific somatic 
mutation spectra to SHM patterns.  For example, in another 
category of human skin cancer Xeroderma Pigmentosum Variant 
(XPV) patients carry genetic deficiencies in DNA Polymerase-η. 
Somatic hypermutation analysis on the J-region proximal 
rearranged VH6 gene in such patients shows a significant reduction 
in mutations at A:T base pairs which allowed Gearhart and 
associates [15] to first show  a clear role for an error-prone 
polymerase (Pol-η) involvement in generating strand biased SHM 
patterns of antibody genes.  
 Our preliminary analysis therefore raises many more 
interesting questions and possibilities for further investigation. 
Further work should establish the sequence context of the A:T 
focused mutations in those tumor types which appear to show them 
(Tables 1b,c,d,e) as it is known that both Pol-η in its DNA-based 
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copying mode as well as the transcription-coupled pre-mRNA editor 
ADAR1 both display selectivity for mutating or deaminating WA-
sites in DNA or RNA (where the 5' W = A or T/U) [11]. Further work 
is also required to establish that the subset of tumor samples 
chosen here is indeed consistent and representative in a wider 
analysis.  
 Whilst there is a clear resemblance between SHM and CGP 
somatic mutation spectra, the resemblance is not complete. Thus in 
SHM, mutations occur more or less equally at A:T and C:G base 
pairs. In comparison, the sample data here (Table1b,c,d,e) shows 
an approximate decrease of mutations at A:T by about 50% and a 
corresponding enrichment of mutations at C:G base pairs. With 
respect to C:G base pair targets it is also evident from Greenman et 
al [5] that an AID or AID-like deaminase not dependent on CpG 
may play a role in most malignant melanoma C:G>T:A mutations 
and in about half of C:G targeted mutations in lung, breast and 
other tumors. It is also evident that G>>C strand bias is not 
evident in the samples of breast ductal carcinomas analysed here. 
Lastly in many of the lung carcinomas there is a prominent strand 
bias signature of G-to-T >> C-to-A , which is far more notable than 
in the SHM spectrum (Table 1a) or non-lung cancer tumors (Table 
1d) suggestive maybe of oxidative damage causing 8oxoG 
mutations in RNA  [16] which can now base pair with A and which 
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are then fixed in DNA by reverse transcription [6] as  G-to-T 
mutations. 
 We conclude that overall there is a striking resemblance 
between the patterns of Ig somatic mutations produced in Germinal 
Center derived hypermutated B lymphocytes, and the various 
cancer samples analysed here. This allows the qualified conclusion 
that mutated or base-modified RNA template intermediates coupled 
to error-prone reverse transcription (via Pol-η) could be responsible 
for the somatic mutation spectrum in cancer genomes. A schematic 
outline of the proposed causal relationship between aberrant Ig 
SHM and the genesis of somatic point mutations in cancer is shown 
in Figure 1. The observed quantitative differences in somatic 
mutation spectra among the cancer samples analysed suggests the 
possible involvement of an RNA intermediate as a part of aberrant 
SHM activity. This in turn suggests potential targets involved in 
SHM such as AID, Pol-η, ADAR1 and modulators of the RNA Pol II 
transcription-coupled repair (TCR) apparatus should be considered 
as possible drug targets in the development of future cancer 
therapies. Additional data analyses are being conducted to 
characterise further the relationships found here. The results also 
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Footnotes to Table 1: Patterns of somatic point mutations 
observed at rearranged Ig loci in mice and various cancer 
genome samples. The right ascending diagonal in each base 
substitution table shows the transitions in bold. 
a. Adapted from Table 1a in Steele 2009 (2). Each frequency is the 
mean percentage of twelve studies involving active immunisation 
and antigen-selection of immunoglobulin VDJ genes expressed in B 
cell clones (hybridomas, single B cells, or targeted VH186.2DJ 
transcripts or genes by nested PCR). PCR hybrid formation has been 
assessed to be non-existent or minimal in these SHM data sets. Not 
shown are the standard errors for each estimate which can be found 
in the original table. b. Frequencies of somatic mutations (as %) in 
pooled data of 13 lung adenocarcinomas involving 456 point 
mutations and involving ~ 495 genes (NCI-H1395, NCI-H1437, 
NCI-H2009, NCI-H2087, NCI-H2122, NCI-H2126, PD0277a, 
PD1342a, PD1351a, PD1352a, PD1353a, PD1414a, PD1418a). The 
level of statistical significance (Chi square,1 df) for deviation from 
1.0 of A over T and G over C mutation ratios are P<0.05 and 
P<0.01 respectively. c. Frequencies of somatic mutations (as %) in 
pooled data of 4 lung small cell carcinomas involving 175 point 
mutations and involving ~ 190 genes (LB 647-SCLC, NCI-H128, 
NCI-H209, NCI-H2171). The level of statistical significance (Chi 
square,1 df) for deviation from 1.0 of A over T and G over C 
mutation ratios are P<0.05 and P>0.05 (NS) respectively.  d. 
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Frequencies of somatic mutations (as %) in pooled data of 12 
breast ductal carcinomas involving 275 point mutations and 
involving ~ 287 genes (HCC 1148, HCC 1187, HCC 1395, HCC 
1937, HCC 1599, HCC 1954, HCC 2157, HCC 2218, HCC 38, 
PD0118a, PD0119a, PD1233a). The level of statistical significance 
(Chi square,1 df) for deviation from 1.0 of A over T and G over C 
mutation ratios are P<0.01 and P>0.05 (NS) respectively.  e. 
Frequencies of somatic mutations (as %) in pooled data of 8 
squamous cell carcinomas, mainly lung involving 117 point 
mutations and involving ~ 103 genes (BB 30-HNC, BB 49-HNC, LB 
771-HNC, PD0248a, PD0251a, PD0269a, PD1369a, PD1379a). The 
level of statistical significance (Chi square,1 df) for deviation from 
1.0 of A over T and G over C mutation ratios are P>0.05 (NS) and 
P<0.05 respectively.  f. Frequencies of somatic mutations (as %) in 
pooled data of 7 skin malignant melanomas, involving 1166 point 
mutations and involving ~ 1087 genes (Colo-829, CP50-MEL-B, 
CP66-MEL, LB 2518-MEL, LB 373-MEL-D, MZ7-Mel). g. Frequencies 
of somatic mutations (as %) in NCI-H2009, a lung adenocarcinoma 
involving 146 point mutations and involving ~ 142 genes. The level 
of statistical significance (Chi square, 1 df) for deviation from 1.0 of 
A over T and G over C mutation ratios are P>0.05 (NS) and P>0.05 
(NS) respectively.  h. Frequencies of somatic mutations (as %) in 
CP66-MEL, a skin malignant melanoma involving 248 point 





































        A   T   C      G     Total 
A      -              10.6        6.3        14.6       31.6      
T     3.1      -       5.3          2.6        11.0       
C     4.3           13.4       -        3.6      21.3     







        A   T   C      G     Total 
A      -               6.4        2.4          5.7       14.4      
T     4.3      -       1.5          2.0          7.9       
C       12.2           14.0       -      10.0      36.4     







        A   T   C      G     Total 
A      -               7.7        0.9          7.7       16.2      
T     0.0      -       4.3          0.9          5.1       
C         6.0           14.5       -        5.1      25.6     







        A   T   C      G     Total 
A      -               3.6        2.9          7.3       13.8      
T     0.4      -       2.9          1.1          4.4       
C         7.3           19.6       -      13.8      40.7     







        A   T   C      G     Total 
A      -               0.3        1.3          1.8         3.3      
T     1.1      -       1.3          0.9          3.3       
C         1.6            45.1       -        0.5      47.3     







        A   T   C      G     Total 
A     -               6.8        0.0          8.2       15.1      
T     2.7      -       2.7          2.1          7.5       
C         6.2            12.3       -       15.7      34.2     







        A   T   C      G     Total 
A      -               0.0        1.6          0.8         2.4      
T     1.2      -       0.8          0.4          2.4       
C         0.0            47.5       -        0.4      48.0     




Table 1 : Patterns of somatic point mutations at rearranged Ig loci in mice and various 
cancer genome samples 




Breast ductal  
carcinoma pool  
Squamous cell 
carcinoma pool   
Malignant melanoma  
pool   
NCI-H2009 lung 
adenocarcinoma   
CP66-MEL malignant 




        A   T   C      G     Total 
A      -               6.3        0.6         12.5       19.4      
T     2.3      -       2.2          1.7          6.3       
C       15.4           12.6       -        4.6      32.6     




Lung small cell 
carcinoma pool  
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